# Dan Lewis

Dan Lewis is a Project Farma life sciences manufacturing leader who works with pharma, biotech, and advanced-therapy organizations on technical operations and manufacturing.

- Profile: https://b2binfluencer.marketing/creators/dan-lewis/
- LinkedIn: https://www.linkedin.com/in/danlewis0
- Topics: artificial-intelligence, leadership, supply-chain
- Based on 16 dated posts, latest 2026-09-30

## Summary

Dan Lewis is useful for practical analysis of biopharma manufacturing, capacity, supply chains, and technical operations.

- Best for: Biopharma manufacturing consultancies and campaigns on radiopharmaceutical supply chains and technical operations.
- Not for: Consumer health sponsored placements or campaigns expecting direct product purchases.
- Check first: Confirm figures, sources, commercial formats, audience data and Project Farma relationship before contact.

### Takeaways

- Manufacturing problems are solved across disciplines, not inside one.
- Big facility investments are about supply-chain control, not just capacity.
- Radiopharmaceuticals are the next oncology platform, and isotope supply is the strategic bottleneck.

## Main ideas

- **Manufacturing problems are solved across disciplines, not inside one of them**: Dan Lewis argues that digital manufacturing and automation now run through the entire facility lifecycle — design, project execution, CQV, start-up, operational readiness and ongoing operations. Optimising engineering, quality, automation or operations separately misses the real constraint; aligning those functions on shared objectives reduces handoffs and speeds delivery to patients.
- **Big facility investments are about supply-chain control, not just capacity**: Dan Lewis reads a company's disclosed capital commitment as a decision about where complex therapies are made and how safely they reach patients. Localising production shortens the supply chain and reduces delivery risk; the size of a commitment signals how seriously the company treats that control. They place individual announcements within a wider pattern of onshoring.
- **Radiopharmaceuticals are the next oncology platform, and isotope supply is the strategic bottleneck**: Dan Lewis argues that while attention went to AI, GLP-1 obesity medicines and antibody-drug conjugates, radiopharmaceuticals have been building quietly into what could become oncology's next major treatment platform. The case rests on four claims: these treatments are transforming precision oncology; AI should improve patient selection and personalised dosimetry; theranostics is changing drug-development economics; and isotope supply may become one of the industry's most valuable strategic assets.
- **Judge AI adoption by operations and governance, not by the model**: Dan Lewis covers AI in pharma through its effects on discovery, manufacturing, supply chain, distribution and workforce capability, as well as the guardrails around it. They relay the view that AI augments scientists rather than replacing them, and treat data governance and human oversight as part of the story, not an afterthought.
- **Keep a wide watch on the whole industry, not just manufacturing**: Dan Lewis prioritises breadth of intake. They use a digest format to track deals, regulatory turnover, job cuts, top-selling drugs, counterfeit-medicine enforcement, EU supply policy and early-stage funding in one post, pairing each item with a short implication instead of building a single argument. This sits alongside deeper thesis posts: the account moves between broad aggregation and occasional analysis.
- **Talent and client-side execution are part of the manufacturing problem**: Dan Lewis treats hiring and relationship-building as strategic, not administrative. In recruiting senior operations leaders, they call for deep industry expertise paired with innovative thinking, and seek people who shape manufacturing rather than simply consult. In their own role, Dan describes deepening partnerships across pharma, biotech and advanced therapy sectors and helping organisations improve speed, predictability and execution across technical operations and manufacturing.

## Work to read

- [Radiopharmaceuticals as oncology's next platform](https://www.linkedin.com/posts/danlewis0_while-much-of-the-industrys-attention-has-activity-7488943302063607808-eWV-)
- [AstraZeneca moves its rare disease portfolio to the United States](https://www.linkedin.com/posts/danlewis0_biotech-manufacturing-astrazeneca-activity-7398729373165486080-O_87)
- [Novartis commits $771M to North Carolina manufacturing](https://www.linkedin.com/posts/danlewis0_lifesciences-biotech-novartis-activity-7402041926163898368-lvUu)
- [Novo Nordisk partners with OpenAI across discovery and supply chain](https://www.linkedin.com/posts/danlewis0_ai-artificialintelligence-drugdiscovery-activity-7449845319816896512-xFEj)
- [SimoTech acquisition and the case for integrated manufacturing disciplines](https://www.linkedin.com/posts/danlewis0_lifesciences-pharmaceuticalmanufacturing-activity-7501687034726625280-gHJ7)
- [The pharma industry roundup](https://www.linkedin.com/posts/danlewis0_latest-pharma-industry-updates-activity-7462166314556477441-20cp)
- [Promotion to Vice President of Client Solutions](https://www.linkedin.com/posts/danlewis0_im-excited-to-share-that-ive-been-promoted-activity-7467192480309039104-6ydi)
- [Project Farma hiring two senior operations roles](https://www.linkedin.com/posts/danlewis0_hiring-lifesciences-biotech-activity-7460427639317741568-962F)

## Brand relationships

- **Project Farma** (employment)
- **PerkinElmer** (mention)
- **SimoTech** (mention)

## Partnerships

Dan Lewis posts on LinkedIn as a Project Farma leader about life sciences manufacturing, covering company deals, plant investments, hiring, and industry news. None of the eight posts is sponsored, discloses a paid partnership, or states a sponsorship offer, media kit, rate card, or partnership inquiry route. Novartis, AstraZeneca, Novo Nordisk, Bristol Myers Squibb, Takeda, Eli Lilly, and other brands appear in industry news items, not as commercial partners; a company hashtag does not indicate payment. These posts do not document a partnership product available to book. Before planning a sponsored placement, ask whether a sponsorship or collaboration format exists and request its terms. Dan Lewis offers close commentary on manufacturing and supply-chain moves—the post on radiopharmaceutical investment across Novartis, Bristol Myers Squibb, AstraZeneca, and Eli Lilly is the clearest example—making the subject-matter overlap for a potential collaboration visible, even though the commercial terms are not.

## Alternatives

- Bilal Bham: Better when the article needs a market-maturity and access-strategy lens on radiopharmaceuticals. Their posts track the first US radioligand therapy approved through an abbreviated generic pathway, the proposed Telix–ITM combination as isotope production moves into corporate strategy, and the argument that differentiation may come from route, formulation, and personalised delivery rather than a new ligand. That is closer to the supply-chain and competitive dynamics a consultancy could build a co-authored piece around.
- Hussain Mooraj: Better when the consultancy wants to widen the campaign from radiopharmaceuticals to advanced therapies access and delivery. Their posts describe the NextGen Therapy EMEA working group and Deloitte's advanced therapies summit, including a sub-$8,000 COGS example, Europe's commercialisation gap, outcomes-based pricing, clinical-to-commercial planning, treatment-site readiness, AI use, and supply-chain enablement. For a thought-leadership article about how manufacturing economics and health-system readiness determine patient access, that is a stronger base than radiopharma-specific trend framing.
- Armin Metzger: Better when the article needs a senior manufacturing and supply-chain operator's view on scaling biologic production and reliable supply. Metzger's posts describe ten years at Ferring, work on manufacturing and supply operations, two FDA approvals, and the opening of Sandoz's high-volume biosimilar manufacturing centre in Lendava, Slovenia, tied to a Bio100 ambition of more than 100 biosimilars by 2040. That gives the consultancy a named facility, a supply-network story, and a quality-and-access frame it can examine.

---
AI-assisted summary of public posts. Audience demographics are not available. Engagement appears only where we checked recent posts. Method: https://b2binfluencer.marketing/methodology/